RedHill Biopharma Ltd.
Business
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal, infectious disease and oncology indications. It markets the FDA‑approved GI product Talicia and advances a clinical‑stage pipeline that includes opaganib, RHB‑107 (upamostat), RHB‑104, RHB‑102 (Bekinda) and RHB‑204. Its business comprises U.S. commercial operations for Talicia, clinical development and regulatory programs, and in‑licensing, out‑licensing and partnering to advance and commercialize candidates. Products and development activities are delivered via U.S. commercial channels, multinational clinical trials and territory‑specific licensees and partners internationally.
Summary from filing dated 2025-04-10
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-429.0K |
| Total assets | $25.34M |
| Total liabilities | $21.08M |
| Stockholders' equity | — |
| Operating cash flow | — |